{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:14:30Z","timestamp":1754144070569,"version":"3.41.2"},"reference-count":34,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Omalizumab has been a valuable option for patients with severe asthma, with increasing data with regard to the effectiveness of omalizumab in patients with allergic bronchopulmonary aspergillosis (ABPA).  <jats:bold>Objective:<\/jats:bold> The objective was to evaluate\n the long-term clinical and functional effectiveness of omalizumab in patients with ABPA.  <jats:bold>Methods:<\/jats:bold> Patients who received omalizumab for ABPA in our clinic between December 2008 and September 2023 were retrospectively evaluated. Data were assessed before the initiation of\n omalizumab, at the first year of treatment, and at the last visits of the patients. Patients with Asthma Control Test (ACT) scores of \u226520, no hospitalization\/emergency admissions due to asthma, a reduced daily oral corticosteroid (OCS) dose, and an increase in forced expiratory volume in\n 1 second (FEV<jats:sub>1<\/jats:sub>) level were considered as complete responders.  <jats:bold>Results:<\/jats:bold> A total of 22 patients (no. men\/women: 11\/11) with ABPA and with a mean age of 53 \u00b1 14.94 years (minimum 27 years, maximum 77 years) were included in the study. Significant increases\n were observed in FEV<jats:sub>1<\/jats:sub> measured at the first year and last visit compared with pretreatment (p\u2009=\u20090.007). In patients who received a mean \u00b1 standard deviation (SD) of 12.73 \u00b1 8.87 mg of methylprednisolone before treatment, the OCS dose decreased to a mean\n \u00b1 SD of 2.45 \u00b1 3.08 mg of methylprednisolone in the first year and a mean \u00b1 SD of 0.36 \u00b1 1 mg of methylprednisolone at the last visit (p\u2009&lt;\u20090.001). Of 22 patients, 21 were treated with OCS, whereas 1 patient refused to use OCS due to corticophobia.\n The mean \u00b1 SD ACT score was 17.50 \u00b1 4.77 (minimum 7, maximum 24) at baseline, increased to 22.23 \u00b1 2.44 (minimum 18, maximum 25) at the first year (p\u2009&lt;\u20090.001), and 23.73 \u00b1 1.88 (minimum 19, maximum 25) at the last visit. A significant decrease in\n asthma attacks and hospitalizations at the first year and last visit after omalizumab treatment was observed (p\u2009&lt;\u20090.001). Nineteen patients (86.3%) responded completely, and three (13.7%) responded partially to omalizumab treatment.  <jats:bold>Conclusion:<\/jats:bold> Omalizumab\n treatment in patients with ABPA resulted in a significant reduction in asthma attacks, hospitalizations, and OCS doses, and in significant increases in FEV<jats:sub>1<\/jats:sub> and ACT scores.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250012","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:34:02Z","timestamp":1751934842000},"page":"280-286","source":"Crossref","is-referenced-by-count":1,"title":["Long-term omalizumab treatment outcomes in patients with allergic bronchopulmonary aspergillosis"],"prefix":"10.2500","volume":"46","author":[{"given":"Fuat","family":"Aytekin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhun","family":"Efe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazan","family":"Beyhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erman","family":"Gidik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozcan","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bekir","family":"Tunca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Celebi Sozener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betul Ayse","family":"Sin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesile Dilsad","family":"Mungan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevim","family":"Bavbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omur","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ccm.2012.02.003","article-title":"Allergic bronchopulmonary aspergillosis","volume":"33","author":"Bains","year":"2012","journal-title":"Clin Chest Med"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaip.2023.04.009","article-title":"Prevalence of Aspergillus sensitization and allergic bronchopulmonary Aspergillosis in adults with bronchial asthma: a systematic review of global data","volume":"11","author":"Agarwal","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/13693786.2012.738312","article-title":"Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults","volume":"51","author":"Denning","year":"2013","journal-title":"Med Mycol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"843763","DOI":"10.1155\/2011\/843763","article-title":"Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis","volume":"2011","author":"Knutsen","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaci.2020.08.029","article-title":"New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis\/mycosis and its validation","volume":"147","author":"Asano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cea.12141","article-title":"Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria","volume":"43","author":"Agarwal","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","article-title":"Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center\u2019s experience with 14 cases","volume":"36","author":"Ayd\u0131n","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"B8","first-page":"425","article-title":"Therapy with omalizumab in patients with severe persistent allergic asthma: a real life data in Turkey","volume":"58","author":"Bavbek","year":"2010","journal-title":"Tuberk Toraks"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2400061","DOI":"10.1183\/13993003.00061-2024","article-title":"Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis\/mycoses","volume":"63","author":"Agarwal","year":"2024","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jmii.2013.10.003","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis","volume":"49","author":"Homma","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"B11","article-title":"Global Initiative for Asthma - GINA Report 2024"},{"key":"B12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2500\/aap.2012.33.3551","article-title":"Chapter 18: allergic bronchopulmonary aspergillosis","volume":"33","author":"Greenberger","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"B13","doi-asserted-by":"crossref","first-page":"2101787","DOI":"10.1183\/13993003.01787-2021","article-title":"A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"59","author":"Agarwal","year":"2021","journal-title":"Eur Respir J"},{"key":"B14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/JAA.S34579","article-title":"Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab","volume":"5","author":"Collins","year":"2012","journal-title":"J Asthma Allergy"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"key":"B16","first-page":"145","article-title":"A case of allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"22","author":"Sastre","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/thx.2010.153312","article-title":"Effects of omalizumab in Aspergillus-associated airway disease","volume":"66","author":"P\u00e9rez-de-Llano","year":"2011","journal-title":"Thorax"},{"key":"B18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients","volume":"52","author":"Nov\u00e9-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1753466620961648","DOI":"10.1177\/1753466620961648","article-title":"Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review","volume":"14","author":"Eraso","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"B20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","article-title":"Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature","volume":"122","author":"Li","year":"2017","journal-title":"Respir Med"},{"key":"B22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12890-023-02696-x","article-title":"Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis with or without allergic rhinitis: a retrospective chart review","volume":"23","author":"Cai","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"crossref","first-page":"e12081","DOI":"10.1002\/clt2.12081","article-title":"Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab","volume":"11","author":"van der Veer","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"B25","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.anai.2019.08.193","article-title":"M206 benralizumab for the treatment of refractory allergic bronchopulmonary aspergillosis","volume":"123","author":"Wong","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1749-6632.2012.06810.x","article-title":"The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis","volume":"1272","author":"Moss","year":"2012","journal-title":"Ann NY Acad Sci"},{"key":"B28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.23822\/EurAnnACI.1764-1489.261","article-title":"Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?","volume":"56","author":"Korkmaz","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40629-018-0087-6","article-title":"Comparison of extended intervals and dose reduction of omalizumab for asthma control","volume":"28","author":"B\u00f6lke","year":"2019","journal-title":"Allergo J Int"},{"key":"B30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaip.2022.12.012","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis","volume":"11","author":"Jin","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10238-023-01267-y","article-title":"Efficacy of omalizumab in adult patients with allergic bronchopulmonary aspergillosis: a multicentre study in China","volume":"24","author":"Chen","year":"2024","journal-title":"Clin Exp Med"},{"key":"B32","doi-asserted-by":"crossref","first-page":"839011","DOI":"10.3389\/fphar.2022.839011","article-title":"Omalizumab and IgE in the control of severe allergic asthma","volume":"13","author":"Gon","year":"2022","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21911\/aai.476","article-title":"Allergic bronchopulmonary aspergillosis: a clinical evaluation of 15 patients and successful omalizumab treatment of five patients","volume":"17","author":"\u00dcnal","year":"2019","journal-title":"Asthma Allergy Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaip.2015.10.020","article-title":"Measuring total IgE is useful in detecting exacerbations in patients with allergic bronchopulmonary aspergillosis receiving omalizumab","volume":"4","author":"Bobolea","year":"2016","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000004\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:32:35Z","timestamp":1752553955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,1]]}},"alternative-id":["1088-5412(20250701)46:4L.280;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250012","relation":{},"ISSN":["1088-5412"],"issn-type":[{"type":"print","value":"1088-5412"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}